When did sofosbuvir and velpatasvir come on the market?

吉三代(sofosbuvir and velpatasvir) was approved by the U.S. FDA in 2016, and was approved by China's State Food and Drug Administration in 2018. Gene III is a fixed-dose combination of a nucleotide analog polymerase inhibitor and a pan-genotypic NS5A inhibitor for the treatment of chronic Hepatitis C virus(HCV) Hepatitis C virus (HCV) infection.

Gen3 is the first direct-acting antiviral agent (DAA) targeting all major HCV genotypes 1 to 6, for use in patients with or without cirrhosis. In clinical studies, 95%to99%of patients without cirrhosis or with mild cirrhosis who received GISANDA had no detectable virus in their blood 12 weeks after completing the 12week regimen. Among patients with moderate to severe cirrhosis, some of whom also required ribavirin therapy, 94% cleared the virus 12 weeks after completing treatment.

Gisanda is an oral tablet to be taken once daily with or without food. It is available in two drug combinations, 400 mgsofosbuvir/100 mg velpatasvir and 200 mg tablets/50 mg tablets. Gisandaalso has oral pellets (200 sofosbuvir/50 velpatasvir and 150/37.5oral pellets)for children who cannot swallow tablets. For children under 6 years of age, take Jisandai oral granules with food to enhance palatability, Children's dosage is based on weight.

There are generic drugs overseas. The officially marketed version has the same ingredients and dosage specifications as the original drug. A course of treatment costs about 3000 or so. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.